Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia

Tyrosine kinase inhibitor treatment of chronic myeloid leukemia (CML) has demonstrated beneficial effects. However, resistance to tyrosine kinase inhibitors and disease relapse are still a challenge for CML therapy. In this study, we analyzed bone marrow samples from 149 CML patients and 15 control...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Ji, Min, Lu, Fei, Pang, Yihua, Dong, Xin, Zhang, Jingru, Li, Peng, Ye, Jingjing, Zang, Shaolei, Ma, Daoxin, Ji, Chunyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113287/
https://www.ncbi.nlm.nih.gov/pubmed/30154435
http://dx.doi.org/10.1038/s41419-018-0900-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113287/
https://www.ncbi.nlm.nih.gov/pubmed/30154435
http://dx.doi.org/10.1038/s41419-018-0900-7

Ejemplares similares